Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 déc. 2025 08h00 HE | Source: Ajax Therapeutics

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

NEW YORK and CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative...
04 déc. 2025 08h00 HE | Source: Ajax Therapeutics

Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease...
19 août 2025 08h00 HE | Source: Ajax Therapeutics

Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC

NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with...